DBV Technologies S.A. (DBVT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Daniel Tassé | CEO & Director | 1.21M | -- | 1960 |
| Dr. Pharis Mohideen | Chief Medical Officer | 725.12k | -- | 1965 |
| Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. | CFO & Principal Accounting Officer | -- | -- | 1969 |
| Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. | Chief Operations Officer | -- | -- | -- |
| Ms. Michele F. Robertson | Chief Legal Officer | -- | -- | -- |
| Ms. Caroline Daniere | Chief Human Resources Officer & Chief of Staff | -- | -- | 1975 |
| Dr. Wence Agbotounou | Chief Clinical Trial Officer & Senior VP | -- | -- | -- |
| Mr. Edward P. Jordan M.B.A. | Senior Vice President of Commercial Operations North America | -- | -- | 1968 |
| Alan Kerr | Senior VP & Head of Global Regulatory Affairs | -- | -- | -- |
| Mr. Pascal Wotling | Chief External Manufacturing & Supply Chain Officer | -- | -- | -- |
DBV Technologies S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 104
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Corporate Governance
Recent Events
- Apr 08, 2024PRE 14A: Proxy StatementsSee Full Filing
- Mar 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 07, 202410-K: Periodic Financial ReportsSee Full Filing
- Dec 22, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 20, 2023S-8: Offering RegistrationsSee Full Filing
Upcoming Events
Upcoming Events Information Not Available